PURPOSE: The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular lymphoma (FL) by using parameters which could not be retrospectively studied before, and by choosing progression-free survival (PFS) as principal end point. PATIENTS AND METHODS: Between January 2003 and May 2005, 1,093 patients with a newly diagnosed FL were registered and 942 individuals receiving antilymphoma therapy were selected as the study population. The variables we used for score definition were selected by means of bootstrap resampling procedures on 832 patients with complete data. Procedures to select the model that would minimize errors were also performed. RESULTS: After a median follow-up of 38 months, 261 events for PFS evaluation were recorded. beta2-microglobulin higher than the upper limit of normal, longest diameter of the largest involved node longer than 6 cm, bone marrow involvement, hemoglobin level lower than 12 g/dL, and age older than 60 years were factors independently predictive for PFS. Using these variables, a prognostic model was devised to identify three groups at different levels of risk. The 3-year PFS rate was 91%, 69%, and 51% for patients at low, intermediate, and high risk, respectively (log-rank = 64.6; P < .00001). The 3-year survival rate was 99%, 96%, and 84% for patients at low, intermediate, and high risk, respectively (P < .0001). CONCLUSION: Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy.

Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project / Federico, Massimo; Bellei, Monica; Marcheselli, Luigi; Luminari, Stefano; Lopez Guillermo, A.; Vitolo, U.; Pro, B.; Pileri, S.; Pulsoni, A.; Soubeyran, P.; Cortelazzo, S.; Martinelli, G.; Martelli, M.; Rigacci, L.; Arcaini, L.; Di Raimondo, F.; Merli, F.; Sabattini, E.; McLaughlin, P.; Solal Céligny, P.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 27:27(2009), pp. 4555-4562. [10.1200/JCO.2008.21.3991]

Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project

FEDERICO, Massimo;BELLEI, Monica;MARCHESELLI, Luigi;LUMINARI, Stefano;
2009

Abstract

PURPOSE: The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular lymphoma (FL) by using parameters which could not be retrospectively studied before, and by choosing progression-free survival (PFS) as principal end point. PATIENTS AND METHODS: Between January 2003 and May 2005, 1,093 patients with a newly diagnosed FL were registered and 942 individuals receiving antilymphoma therapy were selected as the study population. The variables we used for score definition were selected by means of bootstrap resampling procedures on 832 patients with complete data. Procedures to select the model that would minimize errors were also performed. RESULTS: After a median follow-up of 38 months, 261 events for PFS evaluation were recorded. beta2-microglobulin higher than the upper limit of normal, longest diameter of the largest involved node longer than 6 cm, bone marrow involvement, hemoglobin level lower than 12 g/dL, and age older than 60 years were factors independently predictive for PFS. Using these variables, a prognostic model was devised to identify three groups at different levels of risk. The 3-year PFS rate was 91%, 69%, and 51% for patients at low, intermediate, and high risk, respectively (log-rank = 64.6; P < .00001). The 3-year survival rate was 99%, 96%, and 84% for patients at low, intermediate, and high risk, respectively (P < .0001). CONCLUSION: Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy.
2009
27
27
4555
4562
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project / Federico, Massimo; Bellei, Monica; Marcheselli, Luigi; Luminari, Stefano; Lopez Guillermo, A.; Vitolo, U.; Pro, B.; Pileri, S.; Pulsoni, A.; Soubeyran, P.; Cortelazzo, S.; Martinelli, G.; Martelli, M.; Rigacci, L.; Arcaini, L.; Di Raimondo, F.; Merli, F.; Sabattini, E.; McLaughlin, P.; Solal Céligny, P.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 27:27(2009), pp. 4555-4562. [10.1200/JCO.2008.21.3991]
Federico, Massimo; Bellei, Monica; Marcheselli, Luigi; Luminari, Stefano; Lopez Guillermo, A.; Vitolo, U.; Pro, B.; Pileri, S.; Pulsoni, A.; Soubeyran, P.; Cortelazzo, S.; Martinelli, G.; Martelli, M.; Rigacci, L.; Arcaini, L.; Di Raimondo, F.; Merli, F.; Sabattini, E.; McLaughlin, P.; Solal Céligny, P.
File in questo prodotto:
File Dimensione Formato  
613.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 389.13 kB
Formato Adobe PDF
389.13 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/622920
Citazioni
  • ???jsp.display-item.citation.pmc??? 188
  • Scopus 558
  • ???jsp.display-item.citation.isi??? 501
social impact